Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection

Elisabetta Caselli1†, Alessandro Borghi2+†, Martina Maritati2, Roberta Gafà3, Giovanni Lanza3, Dario Di Luca1, Annarosa Virgili2 and Carlo Contini2

Abstract

Background: We have previously reported the case of an immunocompetent female patient with a primary cutaneous CD30+ anaplastic large-cell lymphoma (PCALCL) located on her upper right eyelid characterized by the presence of a concurrent active infection by C. pneumoniae and Human herpesvirus 8 (HHV8). This finding suggested for the first time a possible association of C. pneumoniae and/or HHV8 infection, or both together, with PCALCL pathogenesis in non-immunocompromised and HIV-negative subjects. The subsequent course of the same patient’s medical history is herein reported.

Findings: During the 4 years following the surgical excision of the first PCALCL, the patient developed five further skin lesions located at different anatomical sites, all histologically proven as PCALCLs. The patient underwent several cycles of doxycycline as prophylaxis against Chlamydia. Skin presence of Chlamydia spp and HHV8 was investigated in all recurrences as well as in routine control blood samples. Amplification fragments corresponding to Chlamydia were found in all skin tissues analysed except one (4/5; 80 %), whereas it was not detected in any of the peripheral blood mononuclear cell samples. Conversely, HHV8 was detected in 2/5 (40 %) of the skin biopsies, including the sample negative for Chlamydia, but in all the blood samples analysed.

Conclusions: These findings further support the hypothesis of a potential role of C. pneumoniae and HHV8 infection in the development and course of the described cutaneous lymphoma. A reciprocally promoting interaction between the two pathogens may be supposed to be relevant for PCALC occurrence and relapse.

Keywords: Primary cutaneous CD30+ anaplastic large-cell lymphoma, Chlamydophila pneumoniae, Human herpesvirus 8, Infection-related carcinogenesis
Introduction

Several infectious triggers have been associated with the development of cutaneous lymphomas. However, the actual implication of infectious agents in the pathogenesis of such disorders remains controversial [1–5]. In a previous report [6], we reported the case of an immunocompetent female patient with a primary cutaneous CD30+ anaplastic large-cell lymphoma (PCALCL) of her upper right eyelid, characterized by the presence of a concurrent active infection by *C. pneumoniae* and Human herpesvirus 8 (HHV8). This finding suggested that these microorganisms could be involved in the development of the PCALCL by reciprocally potentiating their pathogenic potential.

Here we report the subsequent course of the same patient’s medical history, with particular regard to PCALCL recurrences and concomitant search for *C. pneumoniae* and HHV8.

Case report

The patient, a 68-year-old woman, during the 4 years following the surgical excision of the first PCALCL on her upper right eyelid (July 2011), which microbiological and molecular examination previously detected *C. pneumoniae* and HHV-8, presented at our Dermatology outpatient Unit for the sequential development of five further skin lesions (Table 1). For all these lesions, histopathological and immunohistochemical analyses revealed the diagnosis of cutaneous CD30+ anaplastic large cell lymphoma, like the first excised tumor [6].

More in detail, in September 2012 the patient presented due to the rapid onset of an erythematous, itching plaque, with a mamillated surface, 12 × 8 mm in diameter, on the right side of the posterior surface of her neck (Fig. 1a). After histological confirmation of a biopsy specimen, the lesion was treated with daily application of topical corticosteroid and oral doxycycline 200 mg/day for 3 weeks because of a possible relapse by *C. pneumoniae*. Two months later, the plaque had resolved leaving a hyperchromic macule. Then, the patient underwent three further 2-week cycles of doxycycline 200 mg/day as prophylaxis against Chlamydia, at 6–8 month intervals.

In June 2013, the woman presented with both a pinkish dome-shaped plaque on her left hemiabdomen (Fig. 1b) and a reddish-brown nodule, with well-defined borders, covered with crust, located on her left commissure of the lips (Fig. 1c). The patient referred the sudden and almost concomitant onset of both lesions, which were surgically excised.

Table 1 PCR results in skin specimens and PBMC from the patient with *C. pneumoniae* and HHV-8 coinfection

| Date         | Clinical samples | PBMC | Pathogens’ detection |
|--------------|------------------|------|----------------------|
|              | Skin samples     |      |                      |
|              |                  |      |                      |
|              | Upper right eyelid (primary occurrence of PALCL) | 1st sample | *Positive*, **Positive* | Positive*; **Positive** | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Positive* | Primary acceptance of consort oligoarray. Shady boxes indicate the absence of the correspondent clinical sample at the indicated date.

*Positive for *C. pneumoniae* 16S gene; **Positive for *C. pneumoniae* HsP60 gene; ^ under tetracycline administration.
In June 2014, an erythematous plaque, 12 × 10 mm in diameter was rapidly developed on the patient right labia majora. The lesion was submitted to complete surgical excision.

In December 2014, the patient presented with a progressively enlarging reddish, finely scaly plaque, located on her upper left eyelid (Fig. 1d). A complete surgical excision of the lesion was performed.

It is worthy of note, that the patient referred that all the PCALCL recurrences occurred in close conjunction with stressful events or periods in her life.

Over the entire lapse of time described, periodical clinical and instrumental follow up of the patient, including positron emission tomography/computed tomography scan of the body, bone marrow biopsy, complete blood count with differential, and blood chemistry including lactate dehydrogenase, showed no evidence of extracutaneous involvement.

In June 2015, the patient addressed the hematologic unit of another hospital and was treated with gemcitabine 1000 mg/m² per day, three administrations per month for a total of three consecutive cycles, due to the previous recurrences of skin lymphomas. The treatment was well tolerated by the patient. In the same period, the patient started a prophylactic treatment with isoniazid, as a latent tuberculosis infection was supposed based on both QuantiFERON test positivity and a computerized tomography scan of the chest.

Up to date, no further skin lesions appeared.

Methods and results
Due to the microbiological findings concerning the first PCALCL lesion, skin presence of Chlamydia spp and HHV8 was investigated in all subsequent recurrences, after receiving informed consent from the patient. Both pathogens were searched in routine control blood samples as well. Approval by the institutional review board of our Hospital was not required for the present study, as materials were not collected specifically for this study, and were completely de-identified.

*C. pneumoniae* was searched in cutaneous biopsies and in peripheral blood mononuclear cells (PBMCs) isolated by density gradient from peripheral blood (Fycoll-paque plus, GE Healthcare Europe GmbH, Milan, Italy) as previously described [6, 7]. DNA was extracted and processed as previously described [7, 8], and assayed by PCR. Molecular analyses included nested-PCR using primer sets targeting 16S rRNA, outer membrane protein (ompA/MOMP), and HsP-60 genomic regions of *C. psittaci*, *C. pneumoniae*, and *C. trachomatis* [7].

In parallel, the same specimens were also used for HHV8 search, performed by two different PCRs specifically designed in the ORF50 and ORF26 genes of HHV8 genome [8]. The analysis of two different genes was undertaken to avoid the risk of false positive/negative results connected with a single gene detection. The laboratory results are summarized in Table 1.

Amplification fragments corresponding to *Chlamydia* were found in all skin tissues analysed except one (4/5; 80 %). On the contrary, it was not detected in any of the PBMC samples. Conversely, HHV8 was detected in 2/5 (40 %) of the skin biopsies, including the sample negative for *Chlamydia*, but in all the blood samples analysed.

Discussion
Primary cutaneous T-cell lymphoma (CTCL) are defined as lymphomas occurring at the skin level, with no
evidence of extracutaneous disease at the time of diagnosis [9]. In particular, primary cutaneous CD30+ T-cell lymphoproliferative disorders are the second most common group of CTCLs and include PCALCL and lymphomatoid papulosis [10]. PCALCL occur predominantly in the adult/elderly population, where show a male predominance. They are characterized by solitary or localized nodules, tumors, or papules that frequently become ulcerated, and histologically present diffuse sheets of large tumor cells with an anaplastic, pleomorphic or immunoblastic cytomorphology, largely expressing (>75 %) CD30. Partial or complete regression may occur, but skin relapses can be observed, as in the case reported. The prognosis of PCALCL is good, with 5-year survival rates between 76 and 96 % [11].

The aetiology of CTCLs is still unclear, although a role for superantigenic activation of T cells leading to accumulation of skin-homing T cells has been suggested [12]. Notably, infectious agents have been suggested to have a role in the etiology of other lymphomas, including some non Hodgkin lymphomas, such as gastric and ocular adnexa MALT lymphomas [13–15]. In fact, some viruses can transform lymphocytes as well as a chronic immune stimulus, caused by persistent viral or bacterial infection, can be associated with the selection of lymphocytic clones potentially resulting in lymphoma development [16].

In the described patient, the initial detection of both C. pneumoniae and HHV8 in the first occurrence of PCALCL on her upper right eyelid, suggested a potential pathogenetic involvement of such agents [6].

Accumulating evidences suggest that Chlamydia spp. may play a role in oncogenesis, due to its tendency to cause persistent infections and chronic antigenic stimulation [17]. In particular, C. pneumoniae has been shown to be present in some CTCL and to induce the expansion of C. pneumoniae-specific T cells throughout the release of Sézary T cell-activating factor (SAF) [18]. Moreover, C. pneumoniae eradication with doxycycline has been reported to result in lymphoma regression in about a half of patients [19]. However, its implication in the pathogenesis of skin lymphomas remains unclear.

On the other hand, herpesviruses have been hypothesized as possible triggers of CTCLs [20, 21]. Among these, HHV8 seems particularly interesting, due to its oncogenic activity: it is causally related to Kaposi’s sarcoma (KS), Multicentric Castleman’s Disease (MCD), and Primary Effusion Lymphomas (PEL), and associated to other lymphoproliferative disorders occurring primarily in immunosuppressed patients [22, 23]. Interestingly, we recently observed a high prevalence of HHV8 in skin biopsies from angiomatous lesions [24], occurring prevalently in immunosuppressed individuals, suggesting that this virus might be involved in the development of skin lesions other than KS. Furthermore, several HHV8 genes can trigger cell transformation, being directly responsible for its oncogenic potential [23].

The results reported herein further support the hypothesis of a potential role of C. pneumoniae and/or HHV8 infection, or both together, in the development and course of the described cutaneous lymphoma. Indeed, the presence of C. pneumoniae was revealed in 4/5 skin PCALCL recurrences, whereas HHV8 DNA was detectable in two cutaneous recurrences only, including the one in which Chlamydia was not detected. On the other hand, the presence of HHV8 was a constant finding in blood PBMCs, whereas C. pneumoniae was no longer detectable in PBMCs after the antibiotic courses suggesting bacterial eradication from this compartment following doxycycline therapy.

The differences in pathogens’ presence in blood and tissue specimens might reflect the peculiar biological behavior of the two pathogens. In fact, similarly to other human herpesviruses, HHV8 establishes lifetime persistence in infected individuals, where 50–100 copies of virus genome per infected cell can be found in peripheral blood lymphocytes/monocytes, which represent the virus reservoir [25, 26]. Consequently, the virus load at tissue level might be lower than in blood, unless the virus is actively replicating in tissues because of reactivation.

By contrast, the reservoir of Chlamydia during persistence is not fully elucidated, although it has been suggested that the gastrointestinal tract might be involved [27]. Moreover, recurrent chlamydial manifestations may result from either repeated infections or persistence of the organism after unresolved but often host damaging infections, and it is not easy to differentiate between persistent infection and reinfection [28]. Accordingly, in our clinical specimens, Chlamydia appeared concentrated in the skin tissue, rather than in blood, where it was apparently eradicated, suggesting that its eventual presence was discontinuous and that antibiotic treatment maintained Chlamydia load undetectable in the blood.

Epidemiological studies have connected human herpesviruses and Chlamydia in several diseases, including endometritis, salpingitis, cervical cancer, chronic fatigue syndrome and multiple sclerosis [29–35]. Moreover, it has been shown that co-infection with HSV-1, HSV-2, HCMV or HHV-6 influences C. pneumoniae replication [36], promoting chlamydial persistence and increasing viral uptake. Interestingly, it was also reported that C. trachomatis induced reactivation of chromosomally integrated HHV6, and that in coinfected women low virus titers correlated with high C. trachomatis load and vice versa, demonstrating a potentially significant interaction of these pathogens in blood cells and in the cervix of infected patients [36]. Moreover, HHV6, CMV and HSV-1
have been reported to induce chlamydial persistence by inducing oxidative stress [36].

Our findings suggest that a similar interaction might occur also between Chlamydia and HHV8. The presence of HHV8 might support the persistence or the reactivation of C. pneumoniae in the skin, where it might induce tissue damage in spite of its apparent eradication in peripheral blood. At the same time, the presence of Chlamydia might facilitate reactivation of HHV8, finally resulting in the development of PCALCL recurrences. Interestingly, the appearance of recurrences following periods of psycho-emotional stress, as in the case reported, highlights the role of impairment of immune surveillance, and further support the hypothesis of a role of endogenous reactivation of the detected pathogens in the observed recurrent diseases.

A limitation of the present study is represented by the absence of transcriptional data, which would have clarified the replicative status of both pathogens in the different clinical specimens, but unfortunately the fresh specimens were not available for this analysis.

Furthermore, future mechanistic studies are needed to understand the interaction between these two pathogens inside a coinfected cell. No studies are in fact reported in the literature about the possible mutual interaction between HHV8 and C. pneumoniae.

Based on our observations, it would be interesting to analyze in vitro their mutual behavior in different cell types (i.e. lymphocytes/monocytes or epithelial cells) coinfected by both pathogens.

Competing interest
The authors declare that they have no competing interests.

Author details
1. Department of Medical Sciences, Section of Microbiology, University of Ferrara, Ferrara, Italy.
2. Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara, Ferrara, Italy.
3. Department of Morphology, Surgery and Experimental Medicine, Section of Pathology and Molecular Diagnostics, University of Ferrara, Ferrara, Italy.

Received: 12 April 2016 Accepted: 18 May 2016
Published online: 05 July 2016

References
1. Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;64:423–31.
2. Yu WW, Hsieh PP, Chuang SS. Cutaneous EBV-positive y6 T-cell lymphoma vs. extranodal NK/T-cell lymphoma: a case report and literature review. J Cutan Pathol. 2013;40:310–6.
3. Du-Thanh A, Fouloungne V, Guillot B, Dereure O. Recently discovered human polyomaviruses in lesional and non-lesional skin of patients with primary cutaneous T-cell lymphomas. J Dermatol Sci. 2013;71:140–2.
4. Du-Thanh A, Dereure O, Guillot B, Fouloungne V. Merkel cell polyomavirus: its putative involvement in a particular subset of cutaneous lymphoma with possibly unfavorable outcome. J Clin Virol. 2014;61:161–5.
5. Mirvish JJ, Pomerantz RG, Falco Jr LD, Geskin LJ. Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol. 2013;31:423–31.
6. Borghi A, Caselli E, Di Luca D, Sebastiani A, Perri P, Seraceni S, Contini C, Vegilli A. Detection of Chlamydiaphila pneumoniae and human herpesvirus 8 in primary cutaneous anaplastic large-cell lymphoma: a case report. Infect Agent Cancer. 2013;8:41.
7. Contini C, Grilli A, Badia L, Guardigni V, Govanni M, Seraceni S. Detection of Chlamydiaphila pneumoniae in patients with arthritis: significance and diagnostic value. Rheumatol Int. 2011;31:1307–13.
8. Caselli E, Fiorentini S, Amici C, Di Luca D, Caruso A, Santoro MG. Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-κB pathway. Blood. 2007;109:2718–26.
9. Willerme R, Jaffe ES, Burg G, Ceroni L, Berti E, Sverdlow SH, Raifkaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Stenry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ, WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.
10. Quintanilla-Martinez L, Jansen PM, Kinney MC, Sverdlow SH, Willemze R. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139:514–514.
11. Kempf W, Pfaltz K, Vermeer MH, Cozzoli A, Ortizzo-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Ceroni L, Berti E, Horwitz S, Princ ile HM, Guitart J, Estrach T, Sanches JA, Ducic M, Ranki A, Dreno B, Ostheeren-Michaels S, Knobler R, Wood G, Willemze R, EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024–35.
12. Linnemann T, Gelfrich S, Lukowski A, Meikle A, Audring H, Sverdlow W, Walden P. Polyclonal expansion of T cells with the TCR V β type of the tumour cell in lesions of cutaneous T-cell lymphoma: evidence for possible superantigen involvement. Br J Dermatol. 2004;150:1013–7.
13. Foster LH, Portell CA. The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas. Curr Treat Options Oncol. 2015;16:28.
14. Chiu BC, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res. 2015;165:1–25.
15. Zucca E, Bentini F, Vannata B, Cavalli F. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res. 2014;20:207–16.
16. Suarez F, Lotholroy O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034–44.

Abbreviations
CTCLs, Cutaneous T Cell Lymphomas; HHV8, Human Herpesvirus 8; MALT, Mucosa-Associated Lymphoid Tissue; MCD, Multicentric Castleman’s Disease; PBMCs, Peripheral Blood Mononuclear Cells; PCALCL, Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphoma; PEL, Primary Effusion Lymphomas.

Acknowledgment
This work was partially supported by local research funds of the University of Ferrara (FAR).

Authors’ contributions
EC contributed to: study concept and design, acquisition of data (virological features), analysis and interpretation of data, drafting of the manuscript. AB contributed to: study concept and design, acquisition of data (clinical features), analysis and interpretation of data, drafting of the manuscript. MM contributed to: acquisition and processing of PBMC specimens, microbiological and molecular data on Chlamydiaphila pneumoniae, analysis and interpretation of data. RG contributed to: study concept and design, acquisition of data (histological features), provision of patient’s samples and provision of support for molecular analysis, revision of the article. GL contributed to: study concept and design, acquisition of data (histological features), provision of patient’s samples and provision of support for molecular analysis, revision of the article. DL contributed to: study concept and design, acquisition of data (virological features), analysis and interpretation of data, revision of the article. AV contributed to: study concept and design, acquisition of data (clinical and histological features), analysis and interpretation of data, revision of the article. CC contributed to: study concept and design, acquisition and processing of PBMC specimens, microbiological and molecular data on Chlamydiaphila pneumoniae, analysis and interpretation of data, drafting of the manuscript. All authors read and approved the final manuscript.
17. Contini C, Seraceni S, Carradori S, Culfrea R, Perri P, Lanza F. Identification of Chlamydia trachomatis in a patient with ocular lymphoma. Am J Hematol. 2009;84:597–9.

18. Abrams JT, Balin BJ, Vonderheid EC. Association between Sezary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:69–85.

19. Ferreti AJ, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Muzzi R, Lettini AA, Demeter J, Dell’Oro S, Doglioni C, Villa E, Boiocchi M, Dolcetti R. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067–73.

20. Nagore E, Ledesma E, Collado C, Oliver V, Perez-Perez A, Allaga A. Detection of Epstein-Barr virus and human herpesvirus 7 and 8 genomes in primary cutaneous T- and B-cell lymphomas. Br J Dermatol. 2000;143:320–3.

21. Heme KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood. 2003;101:2132–6.

22. Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett. 2010;289:140–50.

23. Schulz TF, Cesarman E. Kaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesis. Curr Opin Virol. 2015;14:116–28.

24. Ballestas ME, Kaye KM. The latency-associated nuclear antigen, a multifunctional protein central to Kaposi’s sarcoma-associated herpesvirus latency. Future Microbiol. 2011;6:1399–413.

25. Purushothaman P, Dabral P, Gupta N, Sarkar R, Verma SC. KSHV genome replication and maintenance. Front Microbiol Front Microbiol. 2016;7:54.

26. Tran-Thanh D, Koushik A, Provencher D, Drouin P, Dubuc-Lissoir J, Gauthier P, Allaire G, Kornegay J, Franco E, Coutlée F. Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix. J Med Virol. 2002;68:606–10.

27. Paavonen J, Stevens CE, Wølner-Hanssen P, Critchlow CW, Derouen T, Kiviat N, Koutsky L, Holmes KK. Colposcopic manifestations of cervical and vaginal infections. Obstet Gynecol Surv. 1988;43:373–81.

28. Chen M, Wang H, Woodworth CD, Lusso P, Berneman Z, Kingma D, Delgado G, DiPaolo JA. Detection of human herpesvirus 6 and human papillomavirus 16 in cervical carcinoma. Am J Pathol. 1994;145:1509–16.

29. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Johnson LG, Daling JR. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer. 2007;120:650–5.

30. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS. 2003;111:557–66.

31. Swanborg RH, Whittum-Hudson JA, Hudson AP. Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis - a critical review. Microbes Infect. 2002;4:1327–33.

32. Munger KL, Peeling RW, Hernán MA, Chasan-Taber L, Olek MJ, Hankinson SE, Hunter D, Ascherio A. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology. 2003;14:141–7.

33. Prusty BK, Böhme L, Bergmann B, Sieg C, Krause E, Mehltz A, Rudel T. Imbalanced oxidative stress causes chlamydial persistence during non-productive human herpes virus co-infection. PloS One. 2012;7:e47427.